Clinical trial
A Phase 2 Randomized, Open-Label Study of GS-5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) to Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection
NCT01353248 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Randomized, Open-Label Study of GS-5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) to Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection
- Lead sponsor
- Gilead Sciences
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2011
- Completion date
- March 31, 2013
- Enrollment
- 141 (actual)
- Sites
- 43
Conditions
As the registry lists them; a condition with its own page is linked.